Business
First Disclosure of Global Interim Phase 2 Data for BioNTech and Bristol Myers Squibb PD-L1xVEGF-A Bispecific Antibody Pumitamig (BNT327/BMS986545) in Patients with Extensive-Stage Small Cell Lung Cancer Shows Encouraging Antitumor Activity
PD-L1xVEGF-A bispecific antibody pumitamig (BNT327/BMS986545) plus chemotherapy continues to show encouraging antitumor activity in patients with extensive-stage small cell lung cancer (”ES-SCLC”), expanding evidence for its potential to set a new standard of care in first-line ES-SCLC and beyondGlobal interim Phase 2 data showed a 76.3% confirmed objective response rate (cORR), 100% disease control rate (DCR), a median progression free survival (mPFS) of 6.8 months and a manageable safety profi
About this update from Bristol-myers Squibb Company
[{"type":"image","alt":"BioNTech SE","displaySize":"","headline":null,"caption":"BioNTech SE","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":33,"url":"https://media.zenfs.com/en/globenewswire.com/333ed4c7a82ed16ca3684c6fccef28ab"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/CitAaObWfrAtVDjrB2dw4g--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTQ2O2NmPXdlYnA-/https://media.zenfs.com/en/globenewswire.com/333ed4c7a82ed16ca3684c6fccef28ab","width":300,"height":33}},"lazy":false},{"type":"list","items":[{"val":[{"type":"text","content":"PD-L1xVEGF-A bispecific antibody pumitamig (BNT327/BMS986545) plus chemotherapy continues to show encouraging antitumor activity in patients with extensive-stage small cell lung cancer (”ES-SCLC”), expanding evidence for its potential to set a new standard of care in first-line ES-SCLC and beyond","length":297,"tagName":"p"}]},{"val":[{"type":"text","content":"Global interim Phase 2 data showed a 76.3% confirmed objective response rate (cORR), 100% disease control rate (DCR), a median progression free survival (mPFS) of 6.8 months and a manageable safety profile","length":205,"tagName":"p"}]},{"val":[{"type":"text","content":"Data confirm dose selection for the ongoing global pivotal Phase 3 ROSETTA LUNG-01 trial","length":88,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":590,"olType":false},{"type":"text","content":"MAINZ, Germany, and PRINCETON, USA, September 8, 2025 – BioNTech SE (Nasdaq: BNTX, “BioNTech”) and Bristol Myers Squibb Company (NYSE: BMY, “BMS”) today presented interim data from a global randomized Phase 2 trial (NCT06449209) evaluating pumitamig (also known as BNT327 or BMS986545), an investigational bispecific antibody targeting PD-L1 x VEGF-A, plus chemotherapy in patients with extensive-stage small cell lung cancer (“ES-SCLC”). The data, which are consistent with data presented at the European Lung Cancer Congress (“ELCC”) 2025 from a Phase 2 trial conducted in China (NCT05844150), showed encouraging anti-tumor responses with a positive trend in the secondary endpoint progression free survival. Pumitamig plus chemotherapy demonstrated a manageable safety profile with no new safety signals and a low discontinuation rate. The data are being presented today as a late-breaker oral presentation at the IASLC 2025 World Conference on Lung Cancer (“WCLC”) hosted by the...